Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| VYNE | SC 13G | neutral | 4/10 | Bellevue Group AG, a Swiss asset manager, filed a Schedule 13G disclosing a 10.6% passive stake in Yarrow Bioscience (VY | Oct 7, 2026 |
| GMAB | 6-K | neutral | 2/10 | Genmab held an Extraordinary General Meeting on October 7, 2026, where shareholders approved the Board's 2026 remunerati | Oct 7, 2026 |
| RGEN | SC 13G/A | bullish | 5/10 | FMR LLC (Fidelity) filed an amended Schedule 13G disclosing a 13.0% passive stake in Repligen Corp as of September 30, 2 | Oct 7, 2026 |
| EIKN | SC 13G/A | neutral | 3/10 | FMR LLC (Fidelity) filed an amended Schedule 13G disclosing beneficial ownership of 5,520,152 shares of Eikon Therapeuti | Oct 7, 2026 |
| XFOR | SC 13G/A | neutral | 3/10 | FMR LLC (Fidelity) filed an amended Schedule 13G disclosing a 4.6% passive stake in X4 Pharmaceuticals as of September 3 | Oct 7, 2026 |
| CYCN | SC 13G/A | neutral | 3/10 | FMR LLC (Fidelity) filed an amended Schedule 13G disclosing beneficial ownership of 3,144,797 shares of Korsana Bioscien | Oct 7, 2026 |
| IMCR | SC 13G/A | neutral | 3/10 | FMR LLC (Fidelity) filed an amended Schedule 13G disclosing a passive stake of 1,736,979 shares (3.6%) in Immunocore Hol | Oct 7, 2026 |
| CLDX | SC 13G/A | neutral | 3/10 | FMR LLC (Fidelity) filed an amended Schedule 13G disclosing a 10.7% passive stake in Celldex Therapeutics as of Septembe | Oct 7, 2026 |
| QDEL | SC 13G/A | bullish | 5/10 | FMR LLC (Fidelity) filed a Schedule 13G/A disclosing beneficial ownership of 3,950,167.67 shares of QuidelOrtho Corp com | Oct 7, 2026 |
| ONCO | DEF 14A | bearish | 7/10 | Onconetix (ONCO) filed its definitive proxy statement for the November 10, 2026 annual meeting, seeking shareholder appr | Oct 7, 2026 |
| NGNE | SC 13G | neutral | 4/10 | Prudential Financial Inc. disclosed a passive 11.2% stake in Neurogene Inc. via a Schedule 13G filed on October 7, 2026, | Oct 7, 2026 |
| ALVO | 6-K | neutral | 4/10 | Alvotech announced a long-term strategic manufacturing partnership with LOTTE Biologics, under which LOTTE will manufact | Oct 7, 2026 |
| ANVS | DEFA14A | neutral | 3/10 | Annovis Bio filed a DEFA14A supplement to its proxy statement, postponing the special meeting from October 14 to Novembe | Oct 7, 2026 |
| PHGE | DEF 14A | bearish | 6/10 | Tessera Defense & Homeland Security is holding a special meeting on October 20, 2026 to vote on a proposal to increase s | Oct 7, 2026 |
| CVKD | 8-K | bullish | 6/10 | Cadrenal Therapeutics announced a formal strategic process to maximize shareholder value, engaging Tungsten Advisors as | Oct 7, 2026 |
| ADTX | 25-NSE | bearish | 8/10 | Nasdaq filed a Form 25-NSE to complete the delisting of Aditxt, Inc. common stock, effective October 19, 2026. The delis | Oct 7, 2026 |
| PLSE | 8-K | bullish | 6/10 | Pulse Biosciences announced it has achieved its enrollment target of 164 evaluable patients in the NANOPULSE-AF IDE pivo | Oct 7, 2026 |
| RARE | 8-K | bullish | 6/10 | Ultragenyx entered into an asset purchase agreement on October 6, 2026 to sell a Rare Pediatric Disease Priority Review | Oct 7, 2026 |
| BCDA | 8-K | neutral | 3/10 | BioCardia filed an 8-K announcing a poster presentation of the CardiAMP HF II trial design at the HFSA Annual Scientific | Oct 7, 2026 |
| SPRC | 6-K | neutral | 3/10 | SciSparc announced via press release that its majority-owned subsidiary NeuroThera Labs' subsidiary CliniQuantum achieve | Oct 7, 2026 |
| OPTH | 6-K | neutral | 2/10 | Optimi Health Corp. announced it will present a corporate overview and hold one-on-one investor meetings at the ThinkEqu | Oct 7, 2026 |
| CMND | 6-K | neutral | 3/10 | Clearmind Medicine submitted recommendations to the FDA in response to a public hearing on psychedelic drug therapeutic | Oct 7, 2026 |
| CERO | 8-K | bearish | 6/10 | CERO Therapeutics Holdings has agreed to sell its wholly-owned operating subsidiary (CERo Therapeutics, Inc.) to SRX Glo | Oct 7, 2026 |
| JSPR | 8-K | bullish | 5/10 | Jasper Therapeutics commenced a tender offer to repurchase up to all 12,345,707 outstanding warrants (issued in Sep 2025 | Oct 7, 2026 |
| SYRE | 8-K | bearish | 5/10 | Spyre Therapeutics entered into an underwriting agreement to sell 4,117,648 shares of common stock at $85.00 per share, | Oct 7, 2026 |
| RDHL | 6-K | neutral | 4/10 | RedHill Biopharma received a 180-day extension from Nasdaq, until April 5, 2027, to regain compliance with the $1.00 min | Oct 7, 2026 |
| JSPR | SC TO-I | neutral | 4/10 | Jasper Therapeutics commenced an issuer tender offer to repurchase any and all of its 12,345,707 outstanding warrants (J | Oct 7, 2026 |
| ATYR | SC 13G/A | neutral | 3/10 | Federated Hermes, Inc. filed an amendment to its Schedule 13G, reporting beneficial ownership of 4,965,414 shares of aTy | Oct 7, 2026 |
| ARCT | SC 13G/A | neutral | 3/10 | Federated Hermes, Inc. filed an amended Schedule 13G disclosing beneficial ownership of 1,678,069 shares of Arcturus The | Oct 7, 2026 |
| RDY | 6-K | neutral | 2/10 | Dr. Reddy's filed a 6-K on October 7, 2026, solely to announce the date of its Q2 FY2027 earnings release (October 23, 2 | Oct 7, 2026 |